Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I):



(I)

wherein:

R^1 is phenyl optionally substituted by halogen, cyano, C_{1-4} alkyl or C_{1-4} haloalkyl;

R^2 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl; and,

R^3 is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound of formula (I) as claimed in claim 1 wherein R^1 is phenyl substituted with one, two or three of: halogen, cyano or C_{1-4} alkyl.

3. (Currently amended) A compound of formula (I) as claimed in claim 1 ~~or 2~~ wherein R^2 is hydrogen.

4. (Currently amended) A compound of formula (I) as claimed in claim 1, ~~2 or 3~~ wherein the NH of R^3 is acidic ~~NH of R^3~~ and is part of a ring or part of a substituent on an aryl or heterocyclyl ring.

5. (Currently amended) A compound of formula (I) as claimed in claim 1~~, 2 or 3~~ wherein the OH of R^3 is acidic ~~OH of R^3~~ and is a substituent or part of a substituent on an aryl or heterocyclyl ring.

6. (Currently amended) A compound of formula (I) as claimed in claim 1~~, 2, 3 or 4~~ wherein the NH of R^3 is acidic ~~NH of R^3~~ and is part of a suitably substituted 2-oxo-thiazol-5-yl, 2-oxo-oxazol-5-yl, 2-oxo-imidazol-5-yl, 1H-1,2,3-triazol-4-yl, 4-oxo-1H-1,4-dihydropyridin-3-yl, 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl, 6-oxo-1H-1,6-dihydropyridin-3-yl or 2H-tetrazol-5-yl ring.

7. (Currently amended) A compound of formula (I) as claimed in claim 1~~, 2 or 3~~ wherein R^3 is:

- 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent in the 4-position;
- 2-oxo-oxazol-5-yl having a suitable electron withdrawing substituent in the 4-position;
- 1H-1,2,3-triazol-4-yl having a suitable substituent in the 5-position;
- 4-oxo-1H-1,4-dihydropyridin-3-yl having a suitable electron withdrawing substituent in the 2-position;
- 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl having a suitable substituent in the 3-position and optionally substituted in one or more other ring positions;
- 6-oxo-1H-1,6-dihydropyridin-3-yl having a suitable electron withdrawing substituent in the 2-position and/or the 5-position and optionally substituted in one or more other ring positions;
- 6-oxo-1H-1,6-dihydropyridin-3-yl having CH_2CO_2H on the ring nitrogen and optionally substituted in one or more other ring positions;
- 2H-tetrazol-5-yl;

- a CO_2H, CH_2CO_2H or OCH_2CO_2H group on an optionally substituted phenyl, optionally substituted CH_2Ophenyl or optionally substituted naphthyl ring; or,
- an $NHS(O)_2(C_{1-4}$ alkyl) group on an optionally substituted aromatic heterocyclyl ring;

or, where possible, a tautomer thereof.

8. (Currently amended) A compound of formula (I) as claimed in claim ~~1, 2, 3, 4, 6 or 7~~ wherein R^3 is:

- 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent in the 4-position;
- 1H-1,2,3-triazol-4-yl having a suitable substituent in the 5-position; or,
- 6-oxo-1H-1,6-dihydropyridin-3-yl having C_{1-4} fluoroalkyl or cyano in the 2-position or the 5-position.

9. (Currently amended) A compound of formula (I) as claimed in claim 1, ~~2, 3, 4, 5, 6, 7 or 8~~ wherein the 2-hydroxy group has the stereochemistry shown below:



(I)

10. (Currently amended) A process for preparing a compound as claimed in claim 1, the process comprising reacting a compound of formula (II):



(II)

wherein ~~R^1 and R^2 are as defined in claim 1~~

R^1 is phenyl optionally substituted by halogen, cyano, C_{1-4} alkyl or C_{1-4} haloalkyl; and

R^2 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

with a compound of formula (III):

(III)

wherein L^1 is a leaving group, and

R^3 is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0~~as defined in claim 1~~; in the presence of a base, optionally in the presence of a coupling agent[];[].

11. (Original) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier therefor.

12-13. (Cancelled)

14. (Original) A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.